ArticleInvestigational new drugs2016

LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models.

Darlene Barnard et al.PubMed ↗Publisher ↗

No numbers read from the abstract.